A Fluorescent Probe for Rapid, High‐Contrast Visualization of Folate‐Receptor‐Expressing Tumors In Vivo. (26th February 2020)

• Record Type: Journal Article
• Authors: Numasawa, Koji; Hanaoka, Kenjiro; Saito, Naoko; Yamaguchi, Yoshifumi; Ikeno, Takayuki; Echizen, Honami; Yasunaga, Masahiro; Komatsu, Toru; Ueno, Tasuku; Miura, Masayuki; Nagano, Tetsuo; Urano, Yasuteru
• Is Part Of: Angewandte Chemie. Volume 132:Number 15(2020)
• Page Start: 6071
• Page End: 6076
• Publication Date: 2020-02-26
• Subjects: Krebs -- Chromophore -- Fluoreszenzsonden -- Bildgebung -- Vitamine; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.201914826
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Folate receptors (FRs) are membrane proteins involved in folic acid uptake, and the alpha isoform (FR‐α) is overexpressed in ovarian and endometrial cancer cells. For fluorescence imaging of FRs in vivo, the near‐infrared (NIR) region (650–900 nm), in which tissue penetration is high and autofluorescence is low, is optimal, but existing NIR fluorescent probes targeting FR‐α show high non‐specific tissue adsorption, and require prolonged washout to visualize tumors. We have designed and synthesized a new NIR fluorescent probe, FolateSiR‐1, utilizing a Si‐rhodamine fluorophore having a carboxy group at the benzene moiety, coupled to a folate ligand moiety through a negatively charged tripeptide linker. This probe exhibits very low background fluorescence and afforded a tumor‐to‐background ratio (TBR) of up to 83 in FR‐expressing tumor‐bearing mice within 30 min. Thus, FolateSiR‐1 has the potential to contribute to the research in the field of biology and the clinical medicine. Abstract : Die α‐Isoform des Folat‐Rezeptors (FR‐α) wird in Eierstock‐ und Gebärmutterschleimhautkrebszellen überexprimiert. Während bekannte FR‐α‐NIR‐Fluoreszenzsonden eine hohe unspezifische Gewebeadsorption aufweisen, zeigt die neu entwickelte NIR‐Fluoreszenzsonde FolateSiR‐1 eine geringe Hintergrundfluoreszenz mit einem Tumor/Hintergrund‐Verhältnis von bis zu 83 in FR‐exprimierenden tumortragenden Mäusen.